Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target-Reference-Cited by-同舟云学术

Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target

Published:2023-01-11 Issue:2 Volume:18 Page:251-264
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Liao Yi¹^ORCID,Chin Chan Sean¹²,Welsh Eric A.³,Fang Bin⁴,Sun Luxin⁵^ORCID,Schönbrunn Ernst¹⁵^ORCID,Koomen John M.⁶⁷^ORCID,Duckett Derek R.¹⁷,Haura Eric B.⁸^ORCID,Monastyrskyi Andrii¹⁷⁹^ORCID,Rix Uwe¹⁷^ORCID

Affiliation:

1. Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

2. Cancer Chemical Biology Ph.D. Program, University of South Florida, Tampa, Florida 33620, United States

3. Biostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

4. Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

5. Chemical Biology Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

6. Department of Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

7. Department of Oncologic Sciences, University of South Florida, Tampa, Florida 33620, United States

8. Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

9. Department of Chemistry, University of South Florida, Tampa, Florida 33620, United States

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acschembio.2c00587

Reference62 articles.

1. Fragment-based lead discovery

2. Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis

3. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

4. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

5. Introduction to Fragment-Based Drug Discovery

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent fragment approaches targeting non-cysteine residues;Trends in Pharmacological Sciences;2023-11